Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain

SAN DIEGO, May 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news